Sotoxen (Sotorasib) 120 mg
Sotoxen 120 mg (Sotorasib) is a breakthrough targeted therapy for non-small cell lung cancer.
Manufacturer: Everest Pharmaceuticals. Sotoxen is a generic version of Lumakras. It targets a mutation that was considered "undruggable" for decades.
Mechanism of Action ("Locking the Switch"):
Sotorasib is a KRAS G12C inhibitor. It specifically binds to the mutated KRAS protein in cancer cells and locks it in an inactive state. By "switching off" this protein, it blocks the signals that tell cancer cells to grow and divide uncontrolled.
✅ Key Benefit: Offers a lifeline for patients with KRAS G12C-mutated lung cancer who have progressed after chemotherapy.
Indicated specifically for:
- 🎗️ Non-Small Cell Lung Cancer (NSCLC): Locally advanced or metastatic.
- 🧬 Genetic Requirement: Presence of KRAS G12C mutation is mandatory. A valid FDA-approved test is required before starting treatment.
- For adult patients who have received at least one prior systemic therapy.
Packaging: Bottle of 56 Tablets (120 mg each).
⚠️ ADMINISTRATION PROTOCOL:
- 💊 Standard Dosage: 960 mg orally once daily (Total 8 tablets of 120 mg). Dose reduction may be required based on toxicity.
- 🕒 Timing: Take at the same time every day.
- 🍽️ Food: Can be taken with or without food. Swallow tablets whole; do not chew, crush, or split.
- Do not take a missed dose if more than 6 hours have passed.
- History of Interstitial Lung Disease (ILD) or Pneumonitis.
- Severe hepatic impairment.
- Pregnancy and breastfeeding (embryo-fetal toxicity).
Common side effects to monitor:
- 🚽 Gastrointestinal: Diarrhea (most common), nausea.
- 🦴 Musculoskeletal: Arthralgia (joint pain) or muscle pain.
- ⚠️ Hepatotoxicity: Elevated liver enzymes (ALT/AST). Regular liver function tests (LFTs) are crucial.
- New or worsening cough/shortness of breath (sign of ILD).
Similar products
What Customers Say
No reviews yet
Your review can be the first!